Suzhou Zelgen Biopharmaceuticals Co. Ltd.
Suzhou Zelgen Biopharmaceuticals is a Chinese innovative medicine developer headquartered in Kunshan, Jiangsu province. Its research and pharmaceutical development activities include small-molecule therapies and recombinant protein technologies, with an emphasis on cancers and selected additional diseases. The company conducts drug discovery, clinical research and product development with the objective of bringing proprietary therapeutics into medical use. Its shares are listed on the Shanghai Stock Exchange STAR Market under security code 688266.
Company at a glance
Corporate information
- Company entity
- Suzhou Zelgen Biopharmaceuticals Co. Ltd.
- Headquarters / principal office
- China
- Founded
- Not verified
- Ownership / capital status
- Publicly tradedPublicly listed
- Official corporate reference
- https://zelgen.com/
- LinkedIn company page
- Independent company page not verified
Profile review: 2026-11-08 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Listed issuer and R&D focus
SSE STAR: 688266
small molecules · recombinant proteins
oncology · immune-mediated disease
Last independently verified:
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
Suzhou Zelgen Biopharmaceuticals is a Chinese innovative medicine developer headquartered in Kunshan, Jiangsu province. Its research and pharmaceutical development activities include small-molecule therapies and recombinant protein technologies, with an emphasis on cancers and selected additional diseases. The company conducts drug discovery, clinical research and product development with the objective of bringing proprietary therapeutics into medical use. Its shares are listed on the Shanghai Stock Exchange STAR Market under security code 688266.
Business, technology & evidence
- SecuritiesSSE STAR: 688266
Individual program detail is not recorded. Consult the original sources below.
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
Showing 0 / 0 related items
No cataloged update explicitly mentions this company.
Same-field reading (not company-specific)
Research this company together
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinSources & open questions
- Official issuer and R&D disclosure · Suzhou Zelgen Biopharmaceuticals Co. Ltd. ↗Suzhou Zelgen Biopharmaceuticals Co. Ltd. ·
- Official issuer and R&D disclosure · Suzhou Zelgen Biopharmaceuticals Co. Ltd. ↗Suzhou Zelgen Biopharmaceuticals Co. Ltd. ·
Inclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.